A 10-year retrospective real-world study conducted in Korea has confirmed the long-term effectiveness and safety of AstraZeneca's Soliris (eculizumab) in Korean patients with paroxysmal nocturnal hemoglobinuria (PNH) [89858cb8]. The study, which evaluated 80 adult patients treated with Soliris at 14 medical institutions from December 2009 to January 2020, found that 96.3 percent of patients experienced symptom improvement with Soliris treatment [89858cb8]. The overall 5-year survival rate was 96.2 percent, indicating the potential for long-term symptom-free survival [89858cb8]. Key indicators of PNH, such as intravascular hemolysis and lactate dehydrogenase levels, also showed improvement with Soliris treatment [89858cb8]. Safety evaluations revealed that more than half of the patients did not report any complications during the treatment period [89858cb8]. AstraZeneca plans to continue its research efforts to further enhance its market leadership in the treatment of PNH [89858cb8].